期刊文献+

静滴大剂量氨甲蝶呤/醛氢叶酸治疗血液肿瘤的血药浓度及药效学 被引量:3

Plasma Drug Levels and Pharmacodynamics in Treatment of Leukemia With High Dose Methotrexate/Calcium Folinate
在线阅读 下载PDF
导出
摘要 目的:本文对不同时间静滴大剂量氨甲蝶呤/醛氢叶酸解救治疗血液肿瘤患者的血药浓度进行监测及药效和毒性反应进行研究。方法:采用高效液相色谱法测定氨甲蝶呤的血药浓度,按不同时间静滴大剂量氨甲蝶呤将41例病人分为两组;S组氨甲蝶呤于6h滴完,L组于12h滴完,两组均在滴注完6h开始醛氢叶酸救援。在滴注毕0.8、6、42h采血测定氨甲蝶呤血药浓度。结果:S组药物浓度在0.08h显著高于L组(P<0.01),6、18、42h两组血药浓度无差异(P>0.01)。完全缓解率中位持续完全缓解及中位生存期两组间无显著差异(P>0.05),L组毒性反应明显比S组严重。结论:6h滴完组的疗效比12h滴完组的好。 OBJECTIVES:The plasma levels were determined and the effect and toxic reaction were observed in leukemia patients who received high dose MTX/CF rescue therapy by IV drip in different allotted times.METHODS:The plasma levels of MTX were assayed by HPLC.Based on the duration of IV drip,41 patients were divided into 2 groups;groupS:Drug was dripped in 6 hour′s time,group L:in 12 hour′s time.Six hours after drip,CF rescue began to be given to both groups.Blood were sampled at 0.8,6,42h after drip for drug concentration determination.RESULTS:Drug level of groupS was higher than that of group L at 0.8h postdrip and there were no difference between 2 groups at 6,18,42h postdrip(P>0.01).There were no significant difference between 2 groups in complete remission rate,median persistent rate and median survival period (P>0.05).The toxic reaction was more severein group L.CONCLUSIONS:The therapeutic effect of group S was better than that of group L.
出处 《中国药房》 CAS CSCD 1999年第3期129-130,共2页 China Pharmacy
关键词 氨甲蝶呤 醛氢叶酸 血液肿瘤 治疗 血药浓度 methotrexate/calcium folinate rescue therapy leukemia different drug administration scheme
  • 相关文献

参考文献1

  • 1赵香兰 王建华 等.血清MTX7-OH-MTX的HPLC测定法及其与微生物法大剂量MTX疗法监测应用中的比较[J].药物分析杂志,1988,8(5):278-278.

同被引文献24

  • 1戴华,王强,刘实.小剂量甲氨蝶呤对类风湿关节炎的治疗[J].中国药物与临床,2004,4(7):530-531. 被引量:4
  • 2徐卫群,汤永民,方澄清,宋华,石淑文,扬世隆,任鼎泰,沈红强,钱伯芹.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病排泄延迟分析[J].中华血液学杂志,2005,26(1):15-18. 被引量:66
  • 3任华益.甲氨蝶呤血药浓度监测在骨肉瘤辅助化疗中的应用[J].中国医师杂志,2005,7(7):990-991. 被引量:1
  • 4唐薇,张瑛,杨龙,张峻.66例小儿急淋白血病大剂量甲氨蝶呤化疗血药浓度监测及个体化给药[J].中国现代应用药学,2006,23(6):508-510. 被引量:10
  • 5Watterson J, Toogood I, Nieder M, et al. Excessive spinal cord toxicity from intensive central nervous system-directed therapies[J]. Cancer, 1994,74( 11 ) : 3 034.
  • 6Van Gool SW, Van Kerschaver E, Brock P, et al. Disease-and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies [J]. Leukemia, 2000, 14(12) :2 076.
  • 7Davidson A, Payne G, Leach MO, et al. Proton magnetic resonance spectroscopy( 1H-MRS)of the brain follow- ing high-dose methotrexate treatment for childhood cancer[J]. MedPediatr Oncol, 2000,35( 1 ) : 28.
  • 8Harila-Saari AH, Huuskonen UE, Tolonen U, et al. Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: A study with motor evoked potentials[J]. Med Pediatr Oncol, 2001,36 (3):345.
  • 9Finkelstein Y, Zevin S, Heyd J, et al. Emergency treatment of life-threatening intrathecal methotrexate overdose [J]. Neurotoxicology, 2004,25(3):407.
  • 10Gregorios JB, Gregorios AB, Mora J, et al. Morphologic alterations in rat brain following systemic and intraventricular methotrexate injection: Light and electron microscopic studies[J]. JNeuropathol Exp Neurol, 1989,48( 1 ) : 33.

引证文献3

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部